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Abstract
People living with hiV (PlWhiV) can reasonably expect near-normal longevity, yet many express a willingness to assume 
significant risks to be cured. We surveyed 200 PlWhiV who were stable on antiretroviral therapy (arT) to quantify 
associations between the benefits they anticipate from a cure and their risk tolerance for curative treatments. sixty-five 
per cent expected their health to improve if cured of hiV, 41% predicted the virus would stop responding to medications 
over the next 20 years and 54% predicted experiencing serious medication side effects in the next 20 years. respondents’ 
willingness to risk death for a cure varied widely (median 10%, 75th percentile 50%). in multivariate analyses, willingness 
to risk death was associated with expected long-term side effects of arT, greater financial resources and being employed 
(all P < 0.05) but was not associated with perceptions of how their health would improve if cured.
Keywords: hiV, medication, risk taking, treatment
Introduction
hiV has been transformed from a deadly infection to a chronic 
disease for most individuals with access to antiretroviral therapy 
(arT) [1]. however, controlling the virus with arT does not 
eradicate the disease, and there are long-term harms of living 
with the virus in a latent state [2]. as such, there remains real 
value in the development of a cure. research into this area often 
carries risk of harm for study participants who otherwise would 
be expected to live nearly normal lives both in terms of quality 
and length [3–5].
Despite this risk, there is a growing body of research showing a 
desire among people living with hiV (PlWhiV) on stable therapy 
to participate in curative trials [6–19]. a 2016 global study found 
that 95% were interested in participating in cure studies and 
59% were willing to take ‘substantial risks’ [20]. similar enthu-
siasm has been seen in the Usa, with a recent survey finding 
that a majority of respondents desire to participate in cure studies 
[17]. less research, however, has focused on quantifying this 
desire or on understanding participants’ motivations to undergo 
risky but potentially curative therapies, if such treatments existed.
To date, few studies have explored attitudes towards hiV cure 
in the context of decision sciences. specifically, we know of no 
studies that have explored the health-related utility of PlWhiV vs 
the utility they expect from a cure. Decision researchers commonly 
measure such attitudes using instruments such as the standard 
gamble, which asks participants what risk of death they would 
accept for a health improvement [21,22]. The standard gamble 
is derived from economic axioms of rational choice [23,24]. in 
decision and cost-effectiveness analyses, health-related utilities 
are measured on a 0–1 scale, with 1 being equivalent to experi-
encing perfect health, that is, no reduction in utility from health 
problems. according to decision analytic theories, persons willing 
to accept a 10% chance of death to rid themselves of a health 
problem are signifying that they believe the health condition 
is reducing their utility by 0.1. in addition, these theories hold 
that the greater improvement people expect to receive from an 
hiV cure, the higher their willingness to accept a risk of death 
should be.
in this study, we have explored the willingness of PlWhiV to 
undergo a potential hiV cure, even if that cure carries a risk of 
death. We explored these perceptions not in the context of a 
clinical trial, but in the hypothetical context of an existing cure. 
By focusing on a non-trial setting, we were able to distinguish 
people’s beliefs about how an hiV cure would benefit their lives 
from their willingness to accept risks to benefit other people than 
themselves. in addition, we explored their underlying reasons for 
accepting such risks.
Methods
We surveyed a convenience sample of PlWhiV at clinics associ-
ated with two hospitals in Boston, the Massachusetts general 
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hospital and Brigham and Women’s hospital. Participants were 
18 years or older, living with hiV for at least 6 months, on 
anti-hiV therapy (aside from one ‘elite controller’ who had 
no detectable viral load despite being off therapy), had stable 
cD4 T cell counts and were able to read english. clinical staff 
approached consecutive eligible individuals from June 2015 to 
February 2016 for people scheduled to receive outpatient hiV 
care. Those who completed the survey were given a $10 gift card 
for their time. Because the participants were not identifiable, this 
project received an exemption from the Partners human research 
committee, which serves as the institutional review Board for 
both hospitals.
health-related utility
To evaluate whether survey participants believed a cure would 
affect their current state of health, we used two measures of 
health-related utility. The first (current health rating) asked 
respondents to mark their current health status, with ‘0’ being 
‘equivalent to dead’ and ‘100’ representing ‘best health for 
someone your age’ [25].
The second, the euroQol Five-Dimension Questionnaire (eQ-5D), 
is a standardised instrument for measuring health-related utility 
[26]. The five questions concern mobility, self-care, performance 
of usual activities, pain/discomfort and anxiety/depression. For 
each question, one of three responses can be given, ranging 
from non-issue to significant impairment (e.g. ‘i have no problems 
in walking about’, ‘i have some problems walking about’ or ‘i am 
confined to bed’). We combined responses into a single index 
score ranging from 0 to 1 [27].
Willingness to take risk for a cure
as described earlier, we measured participants’ tolerance for risk 
associated with an hiV cure using the standard gamble method 
of utility elicitation [25]. To do so, we presented each participant 
with a scenario: ‘Medical experts are currently trying to develop 
new treatments and potential cures for hiV in the hopes of 
completely removing hiV from the body. if successful, individuals 
who are cured will no longer need to take hiV medications. 
suppose medical experts have developed a successful treatment, 
but the new treatment is risky. some people who receive the 
treatment will die because of a fatal side effect; the rest will be 
cured of hiV’. in defining hiV cure, we purposely left ambiguity 
about whether the cure would eradicate the virus or, instead, 
lead to medication-free remission, out of recognition that this 
distinction is not always clear to individuals or providers. Then 
we asked two risk questions: (1) ‘if there was a 1 in 100 chance 
you would die by taking this hiV treatment, and a 99 in 100 
chance you would survive and be cured of hiV, would you take 
this treatment?’ (2) ‘if there was a 99 in 100 chance you would 
die by taking this hiV treatment, and a 1 in 100 chance you 
would survive and be cured of hiV, would you take this treat-
ment?’ To promote comprehension, both were accompanied by 
a pictograph showing 100 cartoon figures; the number expected 
to survive and be cured was highlighted in bold. For each ques-
tion, respondents could answer ‘definitely no’, ‘probably no’, 
‘don’t know’, ‘probably yes’ or ‘definitely yes’. These two ques-
tions are designed to familiarise participants with the standard 
gamble question – the extreme values help people recognise 
whether their risk tolerance lies between 1% and 99% or, instead, 
on one of those extremes [28].
Finally, we assessed the maximal risk they would take: ‘if asked 
to take a treatment that included a chance of causing death, 
what is the largest chance of death (0–100 out of 100) would 
you accept in order to be cured of hiV?’
Predicted chance of negative health outcomes with and 
without a cure
according to theories of rational choice, people accept risks only 
when they anticipate potential benefits of an action. Thus, accept-
ing risks for an hiV cure should relate to people’s beliefs about 
how a cure would affect either their health or some other aspect 
of their lives. To assess their beliefs about the health effects of 
a cure, we asked respondents to predict how being cured would 
affect their likelihood of incurring several negative health out-
comes (heart attack, cancer, injury and death) over the next 20 
years, compared with continuing their current hiV treatment 
(1 = ‘reduced a lot’, 3 = ‘no change’ and 5 = ‘increased a lot’). 
heart attack and cancer were included because they are two of 
the most commonly cited harms associated with chronic infection 
and thus could plausibly be affected by a cure. alternatively, risk 
of injury should not change with a cure and was included to 
assess the plausibility of respondents’ predictions.
We also assessed the participants’ long-term concerns regard-
ing arT by asking them to estimate the percent of people who 
would experience one of two events over the next 20 years: (1) 
their hiV infection will stop responding to medical treatment 
and they will develop aiDs, and (2) they will experience serious 
side effects from their hiV medications. Finally, to measure their 
beliefs about how a cure would affect their health, we repeated 
the health rating utility measure described previously, but this 
time asked the respondents to predict their health status in 5 
years, first continuing their current treatment regimen (health 
in 5 years with hiV) and then if cured of hiV (health in 5 years 
with hiV cure). These questions allowed us to measure peo-
ple’s perceptions of how their health would differ with and 
without a cure.
stigmatisation and financial status
The effects of an hiV cure might not be limited to health but 
could affect other aspects of the participants’ lives. To begin 
exploring such factors, we added two questions related to non-
health outcomes known to be influenced by hiV. Previous studies 
have shown that PlWhiV are affected by stigma and by the 
financial burdens of managing their illnesses [29,30]. To evalu-
ate perceptions of social stigma, we asked, ‘how much do you 
consider yourself stigmatised by the people who are aware of 
your hiV status?’ (1 = ‘not at all stigmatised’ and 5 = ‘extremely 
stigmatised’). To evaluate financial status, we asked the partici-
pants whether their current household’s financial situation was 
best characterised as one of the following: ‘after paying the bills, 
you still have enough money for special things that you want’; 
‘You have enough money to pay the bills, but little money to buy 
extra or special things’; ‘You have money to pay for the bills, but 
only because you have cut back on things’ or ‘You are having 
difficulty paying the bills, no matter what you do’ [31–33].
Demographics
We collected data on participants’ age, sex, education, employ-
ment status (currently employed: yes or no) and years since being 
diagnosed with hiV.
Data analysis
Our primary outcome of interest is the maximum risk of death 
(from 0 to 100) that participants would accept to be cured of 
hiV. For those analyses, we excluded participants (n = 21) who 
did not respond to the maximum risk of death question. in sec-
ondary analyses, we also excluded people who were inconsistent 
across the three risk questions: those who answered definitely 
yes or definitely no to either the 1% risk of death question or 
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the 99% risk of death question and then contradicted themselves 
in later responses. For example, we considered persons to be 
inconsistent if they said definitely no to taking a 1% risk of death 
and then stated a maximum risk greater than 1%. Based on these 
criteria, 24 of the remaining 179 respondents provided inconsist-
ent responses, leaving 155 respondents who answered all three 
standard gamble questions consistently. in all other analyses, we 
report numbers reflecting the total number of people who answered 
the item in question.
Predictors of willingness to take risk
We conducted both bivariate and multivariate regression analyses 
to determine which variables were associated with people’s will-
ingness to take risk for an hiV cure. We first ran analyses including 
all 179 participants who responded to the maximum risk question, 
and then again with only the 155 participants who gave consist-
ent responses. We ran a spearman’s correlation to exclude collinear 
variables from our multivariate regression analysis.
Results
respondent characteristics
Two hundred individuals completed the survey. Their mean age 
was 51.9 years (sD = 10.4), with 65% male (Table 1). The median 
length of time since hiV diagnosis was 19 years [interquartile 
range (iQr) = 13–24], the median length of time on arT was 15 
years (iQr = 9–20) and 58% had received at least some college 
education. The average eQ-5D score for our population was 0.79 
(sD = 0.20, scale ranges from 0 to 1). The average current health 
score was 77.6 (sD = 16.7, scale ranges from 0 to 100), which, 
if interpreted as a health-related utility score, yields a value of 
0.78, very similar to that provided by the eQ-5D.
Willingness to take risk
When asked if they would take a ‘1 in 100’ chance of death to 
be cured, 73% answered that they ‘definitely’ or ‘probably’ would, 
and 16% stated they probably or definitely would not.  When 
asked if they would take a ‘99 in 100’ chance of death, 26% 
said they definitely or probably would, while 63% answered they 
probably or definitely would not.
For the question on the ‘largest chance of death (0–100) you 
would accept in a cure trial’, the median response was 10% 
(Figure 1). While 18% (32 of 179) said that they would not take 
any risk of death in pursuit of a cure, more than a quarter (26%) 
said they would accept a greater than 50% chance of death.
concerns surrounding the long-term efficacy  
of antiretrovirals
The median estimated probability that the virus would stop 
responding to medications was 30% (iQr = 10–50), with 41% 
Table 1. characteristics of PlWhiV completing a survey on hiV cure 
(N = 200)
Characteristics All participants
age (years), mean (sD) 51.9 (10.4)
sex
 Female/male (%) 35.4/64.6
education, n (%)
 some high school 31 (16.6)
 high school graduate 48 (25.7)
 some college 61 (32.6)
 college graduate 36 (19.3)
 Postgraduate degree 11 (5.9)
employed, n (%) 83 (42.8)
household financial situation after paying 
bills, n (%)
 still have money 55 (30)
 little spare money 64 (35)
 cutback on things 30 (16)
 Difficulty no matter what 34 (19)
Years since hiV diagnosis, median (iQr) 19 (13–24)
Years on hiV medications, median (iQr) 15 (9–20)
Utility scores
current health (0–100), M (sD) 77.6 (16.7)
eQ-5D (0–1), M (sD) 0.79 (0.20)
iQr: interquartile range; PlWhiV: people living with hiV.
Figure 1. stated risk tolerance on a continuous scale. The x-axis is not proportional to highlight responses of interest
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Figure 2. Participant expectations for their antiretroviral medications over the next 
20 years. Boxes represent the interquartile range. The centre line is the 
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Figure 3. current health and predicted health in 5 years, with and without a cure. Boxes represent the interquartile range. The centre line is the median and the whiskers show the 
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of the respondents estimating this risk to be at or greater than 
50% (Figure 2). similarly, the median estimated probability that 
participants would experience serious side effects from medica-
tions was 50% (iQr = 15–70).
stigmatisation
nearly 80% (154 of 196) of the participants reported some 
degree of stigma, with a third reporting that they were either 
‘very’ (19%) or ‘extremely’ (15%) stigmatised.
Predictions of how hiV cure would affect health and 
health-related utility
When asked to estimate health status 5 years from now if cured, 
respondents predicted an average health rating of 89.1 (sD = 12.0). 
When asked to predict health status in 5 years if antiretrovirals 
were continued, respondents predicted an average health rating 
of 77.7 (sD = 17.3) (Figure 3). More than half of the respondents 
anticipated that a cure would reduce their chance of having a 
heart attack, being diagnosed with cancer or death in the next 
20 years (55%, 57% and 59%, respectively) (Figure 4). Only 
20% of the participants expected their chance of injury to change 
if they were cured of hiV.
Predictors of willingness to take risk
Table 2 presents bivariate and multivariate regression analyses. 
in the bivariate analyses, five variables were positively associated 
with the maximum risk of death participants said they would be 
willing to take for a cure: (1) being employed, (2) having higher 
financial status, (3) expecting no response to their current hiV 
medications in 20 years, (4) expecting side effects from their 
medications in 20 years and (5) rating their current health-related 
quality of life (per eQ-5D scale) less highly. These same five 
variables were associated regardless of whether we analysed all 
respondents or only those who provided consistent answers to 
the three risk questions. in multivariate analyses, three variables 
were positively associated with people’s willingness to take risk: 
(1) being employed, (2) having a higher financial status and (3) 
expecting side effects from their medications in 20 years.
Discussion
Many PlWhiV in our study reported being willing to accept a 
substantial risk of death to potentially be cured of hiV. 
specifically, despite being stable on arT, a quarter of our respond-
ents were willing to accept a 50% or greater risk of death to 
achieve an hiV cure, and 10% were willing to accept a 90% or 
greater risk of death. Willingness to accept such risks was strong-
est among those with current jobs, greater financial security and 
a greater sense that they would expect long-term side effects 
from arT. One potential explanation for this enthusiasm to accept 
treatment risks is a belief that a cure would substantially improve 
health. a majority of participants thought that their present health 
not only would be maintained with a cure but also would improve, 
such that current health problems other than hiV would also be 
modestly reversed by a cure. in addition, many respondents 
believed that a cure would substantially reduce their risk of heart 
attack and cancer over the next 20 years.
rational choice theories? Theories of rational choice hold that 
people should only accept risks if those risks will be outweighed 
by potential benefits. in other words, it would be irrational to 
accept a substantial risk of death to be cured of hiV if a cure 
would have little or no impact on one’s life. however, we can 
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Table 2. Predictors of willingness to risk death for an hiV cure
Characteristic
Willingness to take risk – bivariate analysis*
Willingness to take risk 
– multivariate analysis*
All (n = 179)
Consistent answers 
(n = 155) All (n = 179)
Coefficient P Coefficient P Coefficient P
current health rating (0–100) –0.305 0.060 –0.326 0.055
general health (1–5) 0.480 0.863 –0.217 0.942 –3.647 0.260
eQ-5D index score –43.631 0.001 –44.183 0.001 –25.171 0.166
change in health with cure compared with 
current
0.251 0.150 0.340 0.059
Difference in health without cure in 5 years –0.019 0.922 0.057 0.774 –0.015 0.945
expect side effects in 20 years 0.186 0.044 0.199 0.042 0.206 0.049
expect no response in 20 years 0.281 0.002 0.276 0.006
stigma –1.259 0.524 –2.688 0.199 2.680 0.270
Finances 7.156 0.005 9.088 0.001 6.226 0.050
subjective numeracy scale –1.366 0.519 –3.536 0.115 0.765 0.750
Years with hiV –0.292 0.353 –0.581 0.074 –0.340 0.348
Years on hiV medications –0.054 0.876 –0.397 0.281
risk of heart attack 2.482 0.398 0.758 0.814
risk of cancer 1.275 0.660 –0.219 0.944
risk of injury –4.707 0.257 –8.624 0.084
risk of death 3.605 0.221 0.590 0.857
age 0.127 0.621 0.043 0.874
sex 2.539 0.647 4.391 0.450 7.986 0.221
education –4.382 0.070 –4.645 0.069
employment 12.655 0.018 12.960 0.019 15.015 0.022
*Values in bold indicate statistical significance of P < 0.05.
eQ-5D: euroQol Five-Dimension Questionnaire.
ask: how realistic are people’s expectations of an hiV cure and 
would they align with our current understanding of a potential 
cure’s likely benefits? in other words, we can ask whether a 
person’s willingness to accept risk for a cure is driven by inac-
curate beliefs about how a cure would affect either their current 
or future health-related quality of life. For example, approximately 
one-third of our respondents believed that an hiV cure would 
substantially reduce their future risk of heart attack. While an 
antiretroviral medication such as abacavir may increase the likeli-
hood of a cardiovascular event over a lifetime, the absolute risk 
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of such an event occurring is substantially lower than the risk of 
death proposed in our hypothetical cure scenarios [34]. similarly, 
hiV infection has been shown to increase cancer rates, but the 
true risk in the age of combination arT has not been well defined 
[35]. nevertheless, approximately one-third of our respondents 
believed an hiV cure would substantially reduce the risk of cancer, 
raising questions about whether their beliefs about the benefits 
of an hiV cure are partially misinformed.
another reason to pursue a potentially risky cure would be to 
avoid experiencing a decline in the effectiveness of arT therapy 
over time. indeed, many of our respondents expressed scepticism 
regarding the continued tolerability and effectiveness of their 
current treatments. as has been demonstrated previously, reduc-
tion in uncertainty is one of the primary benefits people anticipate 
an hiV cure would provide [19]. nevertheless, mortality from 
treatment failure is uncommon [36]. One study on the three 
original antiretrovirals found that the likelihood of triple therapy 
failure was less than 10% at 10 years, and 90% of those who 
experienced failure were alive 5 years later [37]. These worries 
about medications can lead to psychological distress, and concerns 
surrounding the likelihood of antiretroviral failure appear to be 
exaggerated in our population.
While our survey primarily explored people’s perceptions of how 
an hiV cure would affect their health, the benefits of cure go 
beyond health. We only explored two such non-health outcomes 
related to hiV: stigma and financial well-being. The vast majority 
of respondents (79%) stated that they experience at least some 
stigmatisation from hiV. These findings are similar to those of a 
global study from 2012 that found 78% of hiV-positive people 
experienced some kind of stigmatisation associated with their 
status [38]. While the data presented here cannot be used to 
directly infer whether stigma influenced risk tolerance, freedom 
from stigma could be a motivating factor for trying a risky cure. 
similarly, PlWhiV experience disease-related expenses that poten-
tially reduce their financial well-being. Moreover, in fact, financial 
well-being was one of the few measures we collected that was 
associated with people’s willingness to accept risks for a cure.
Our study had several limitations. First, survey responses were 
collected from a convenience sample at two hospital-based clinics 
in the same city and were not generalisable to a broader popula-
tion. For example, a younger population more recently infected 
with hiV could have different perceptions of the risks and benefits 
of a cure versus respondents like those in our study, most of 
whom had experienced lengthy suppression of the virus with 
antiviral therapy. second, participants indicated their willingness 
to take risk from a hypothetical cure. Third, the survey focused 
on an ambiguous definition of ‘cure’, describing that a cure would 
mean people would not need to take medications but not clarify-
ing whether it would involve eradication of the virus or, instead, 
medication-free remission [2]. Future surveys should include 
questions on remission, its meaning and its desirability to indi-
viduals. Fourth, a substantial number of participants had difficulty 
with the risk measure, resulting in a high rate of inconsistent 
responses. These difficulties could explain the lack of association 
between the risk measure and their beliefs about how a cure 
would affect their long-term health. Of note, previous research 
has also found problems with people’s ability to comprehend 
standard gamble utility questions [39]. it is likely that survey 
elicitations of that measure will not accurately capture people’s 
risk attitudes. Fifth, our study is correlational, not experimental. 
Thus, we can test which responses on our survey are correlated 
with respondents’ willingness to risk death for a cure. however, 
we cannot state whether any of those relationships are causal. 
sixth, we included measures of stigma and financial security, but 
not many other important life domains that are potentially affected 
by hiV. Future research should explore what PlWhiV believe 
about how cure would affect other life domains.
in summary, many people are willing to accept a relatively high 
risk of death to achieve an hiV cure despite being stable on arT. 
Further research should continue to explore the reasons for such 
willingness, employing measures of risk tolerance that are easier 
for people to understand and testing the extent to which people’s 
willingness to incur risks for a cure are influenced by mispercep-
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